Cidara Therapeutics Inc. (CDTX) will host a Key Opinion Leader (KOL) meeting on its rezafungin and Cloudbreak programs on November 14, in New York City for institutional investors, sell-side analysts and business development professionals.
Who are the KOLs?
- Neil J. Clancy, MD, University of Pittsburgh
- Kieren Marr, MD, Johns Hopkins University School of Medicine
- Allison McGreer, MD, University of Toronto
What will the KOLs discuss?
These KOLs will discuss unmet medical need in the treatment and prevention of fungal and viral diseases.
What will they Present?
Cidara’s management team will offer an update on their core pipeline activities including rezafungin, a novel echinocandin antifungal drug in Phase III development as well as Cloudbreak antiviral conjugates (AVCs), potential single dose universal protectants and treatments for influenza and other viral diseases. Cidara will also look at commercial opportunity for rezafungin and AVCs for influenza.
What is rezafungin?
Rezafungin is a novel molecule in the echinocandin class of antifungals, considered to be the safest class of antifungals. It is a broad-spectrum, long-lasting echinocandin with demonstrated potent in vivo activity against representative strains of: Candida spp, Aspergillus spp, Pneumocystis spp and dermatophytes.
The investigational drug is being studied to address unmet need including: 1) First-line therapy of candidemia and invasive candidiasis and 2) Prophylaxis (prevention) of invasive fungal disease, including caused by candida, Aspergillus and Pneumocystis spp.
Who is Cidara?
Based in San Diego, Cidara is a clinical-stage biotech venture focusing on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase III clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE). Cidara is also advancing a second Phase III trial of once-weekly rezafungin for prophylaxis against invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation (ReSPECT) initially in Europe and Canada. Additionally Cidara is applying its proprietary Cloudbreak® platform to develop antiviral diseases. The Cloudbreak platform is designed to discover compounds that both directly kill pathogens and direct a patient’s immune system to attack and eliminate pathogens.
Founded in 2012, they have raised over $121 million. At $2.21 per share their current market capitalization is $65.3 million. Like many emerging biotechs, they are pre-revenue and will lose about $66 million on an annual basis. They hold about $44 million cash in the bank. They floated an IPO in April 2015.Source: Cidara Therapeutics